Case report identifies drug-related problems in a patient with hepatic cirrhosis and chronic hepatitis B, suggesting a need for careful monitoring.
Background: Liver cirrhosis is a chronic liver disease characterized by fibrosis and replacement of normal liver tissue with abnormal nodules. The main etiologies include hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD). The prevalence of liver cirrhosis based on autopsy findings is around 2.4% in Western countries, while in the United States it is estimated at 360 per 100,000 population, causing approximately 35,000 deaths annually. Objective: This case report aims to describe the treatment and identify drug-related problems (DRPs) in a patient diagnosed with PNSD CTP B liver cirrhosis, chronic hepatitis B, dyspepsia syndrome, hypoalbuminemia, and impaired liver function. Method: This study employed a case report design with primary data obtained from patient interviews and retrospective documentation review. Data were analyzed using the SOAP method to identify DRPs. Results: The analysis revealed minor drug interactions, including spironolactone–furosemide, tenofovir disoproxil fumarate (TDF)–morphine sulfate tablet (MST), and cefixime–furosemide. Conclusion: Patients with complex comorbidities are at increased risk of DRPs. Continuous pharmacotherapy monitoring is essential to minimize toxicity and adverse effects.
No takes yet. Share an insight, caveat, or question.
Husnawati et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: